DiaMedica Therapeutics (DMAC) Competitor Comparison
We are evaluating the key criteria listed to compare DiaMedica Therapeutics (DMAC) against its competitors in the Biotechnology industry.
Market Capitalization
258 / 368Gross Profits
0 / 278Total Revenue
0 / 300EBITDA
79 / 337Free Cashflow
101 / 352Quick Ratio
21 / 357Earnings per Share
81 / 359Dividend yield
0 / 6Total Cash
260 / 358Performance 3 years
104 / 368Performance 5 years
93 / 368Performance 10 years
107 / 368Linearity 3 years
7 / 368Linearity 5 years
54 / 368Linearity 10 years
147 / 368Total Rank
108 / 368Dividend Rank
109 / 368Valuation Rank
285 / 368Piotroski Rank
68 / 368Muliplier Rank
330 / 368Gross Profits - DMAC ranking 0 / 278
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.